Screener
Vaxcyte, Inc. PCVX Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders' Equity | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 147 | 134 |
| Additional paid-in capital | 5,478,270 | 4,838,736 |
| Accumulated other comprehensive loss | (6,834) | 1,587 |
| Accumulated deficit | (2,475,569) | (2,154,947) |
| Total stockholders' equity | 2,996,014 | 2,685,510 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s common stock par value per share?
- Vaxcyte, Inc. (PCVX) reported common stock par value per share of $0.00 in Q1 2026.
- How has Vaxcyte, Inc.'s common stock par value per share changed year-over-year?
- Vaxcyte, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Vaxcyte, Inc.'s common stock par value per share?
- Over 2 years (2023 to 2025), Vaxcyte, Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Vaxcyte, Inc.'s common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude